821016-23-3

Upstream product

• 412327-07-2 [(4-methoxyphenyl)methyl] hydrazine dihydrochloride 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 824-94-2 p-methoxybenzyl chloride 
• 140-69-2 4-methoxybenzylhydrazine 

Downstream Products

• 821016-28-8 1-[5-hydroxy-1-(4-methoxybenzyl)-1H-pyrazol-4-yl]ethanone 
• 821016-52-8 (4E)-4-dimethylaminomethylene-2-(4-methoxybenzyl)-2,4-dihydro-3H-pyrazol-3-one 
• 821016-30-2 1-[5-hydroxy-1-(4-methoxybenzyl)-1H-pyrazol-4-yl]propan-1-one 
• 821016-34-6 [5-hydroxy-1-(4-methoxybenzyl)-1H-pyrazol-4-yl](2-thienyl)methanone 
• 821016-32-4 [5-hydroxy-1-(4-methoxybenzyl)-1H-pyrazol-4-yl](phenyl)methanone 
• 821016-36-8 (2E)-1-[5-hydroxy-1-(4-methoxybenzyl)-1H-pyrazol-4-yl]-3-phenylprop-2-en-1-one 
• 821016-26-6 1-(4-methoxybenzyl)-1H-pyrazol-5-ol 

Relevant academic research and scientific papers

PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS

Described herein are compounds that activate pyruvate kinase R, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I): Formula (I) wherein R', R2, L', and L2 are as defined herein.

The 4-methoxybenzyl (PMB) function as a versatile protecting group in the synthesis of N-unsubstituted pyrazolones

Starting from diethyl ethoxymethylenemalonate and 4-methoxy-benzylhydrazine (PMB-NHNH2) 2-(4-methoxybenzyl)-2,4-dihydro-3H-pyrazol-3-one was prepared. Reaction of the latter with carboxylic acid chlorides/calcium hydroxide in 1,4-dioxane afforded 4-acyl-5-hydroxy-1-PMB-1H-pyrazoles, whereas with dimethylformamide diethyl acetal or benzaldehyde the corresponding (E)-4-dimethylaminomethylene or (E)-4-benzylidene products, respectively, were obtained. The PMB protecting group could be conveniently removed from the pyrazole nucleus by treatment with trifluoroacetic acid to give the N-unsubstituted pyrazolones. Detailed NMR spectroscopic investigations ( 1H, 13C, 15N) with the obtained compounds are presented.